» Authors » Meijie Tian

Meijie Tian

Explore the profile of Meijie Tian including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 372
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Li P, Tian Y, Yang K, Tian M, Zhu Y, Chen X, et al.
Adv Biotechnol (Singap) . 2025 Jan; 2(4):32. PMID: 39883349
The use of nitrogen-fixing bacteria in agriculture is increasingly recognized as a sustainable method to boost crop yields, reduce chemical fertilizer use, and improve soil health. However, the microbial mechanisms...
2.
Tian M, Wei J, Cheuk A, Milewski D, Zhang Z, Kim Y, et al.
Nat Commun . 2024 Jul; 15(1):6222. PMID: 39043633
Chimeric antigen receptor (CAR) T-cells targeting Fibroblast Growth Factor Receptor 4 (FGFR4), a highly expressed surface tyrosine receptor in rhabdomyosarcoma (RMS), are already in the clinical phase of development, but...
3.
Yang S, Tian M, Dai Y, Wang R, Yamada S, Feng S, et al.
Sci Immunol . 2024 Jul; 9(97):eadm7908. PMID: 38996009
Infections and neurodegenerative diseases induce neuroinflammation, but affected individuals often show nonneural symptoms including muscle pain and muscle fatigue. The molecular pathways by which neuroinflammation causes pathologies outside the central...
4.
Tian M, Wei J, Shivaprasad N, Highfill S, Gryder B, Milewski D, et al.
Cell Rep Med . 2024 May; 5(5):101586. PMID: 38723625
No abstract available.
5.
Tian Y, Li P, Chen X, He J, Tian M, Zheng Z, et al.
Ecotoxicol Environ Saf . 2024 May; 278:116418. PMID: 38696873
Microorganisms have a significant role in regulating the absorption and transportation of Cd in the soil-plant system. However, the mechanism by which key microbial taxa play a part in response...
6.
Tian M, Wei J, Shivaprasad N, Highfill S, Gryder B, Milewski D, et al.
Cell Rep Med . 2023 Sep; 4(10):101212. PMID: 37774704
Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is...
7.
Masih K, Gardner R, Chou H, Abdelmaksoud A, Song Y, Mariani L, et al.
Blood Adv . 2023 Jan; 7(15):4218-4232. PMID: 36607839
CD19 chimeric antigen receptor T-cell therapy (CD19-CAR) has changed the treatment landscape and outcomes for patients with pre-B-cell acute lymphoblastic leukemia (B-ALL). Unfortunately, primary nonresponse (PNR), sustained CD19+ disease, and...
8.
Tian M, Cheuk A, Wei J, Abdelmaksoud A, Chou H, Milewski D, et al.
J Clin Invest . 2022 Jul; 132(16). PMID: 35852863
Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated antigens (TAAs), limited T cell...
9.
Gao Y, You M, Fu J, Tian M, Zhong X, Du C, et al.
J Hepatol . 2021 Oct; 76(1):148-159. PMID: 34689996
Background & Aims: Regulatory T cell (Treg) depletion increases antitumor immunity. However, severe autoimmunity can occur following systemic loss of Tregs, which could be avoided by selectively depleting intratumoral Tregs....
10.
Li N, Torres M, Spetz M, Wang R, Peng L, Tian M, et al.
Cell Rep Med . 2021 Jul; 2(6):100297. PMID: 34195677
Targeting solid tumors must overcome several major obstacles, in particular, the identification of elusive tumor-specific antigens. Here, we devise a strategy to help identify tumor-specific epitopes. Glypican 2 (GPC2) is...